title: [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee].
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage; D005762:Gastroenterology / Q000592:standards*; D005858:Germany; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D007388:Internal Medicine / Q000592:standards*; D000069616:Simeprevir; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D013449:Sulfonamides; D000069616:Simeprevir